| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nussara Pakvisal, Richard M Goldberg, Chirawadee Sathitruangsak, Witthaya Silaphong, Satawat Faengmon, Nattaya Teeyapun, Chinachote Teerapakpinyo and Suebpong Tanasanvimon |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Suebpong Tanasanvimon, Assistant Professor, MD, Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, 1873 RAMA IV Road, Bangkok 10330, Thailand. surbpong@yahoo.com |
| Key Words |
Metastatic colorectal cancer; Anti-epidermal growth factor receptor; Frontline; Subsequent line; RAS wild type metastatic colorectal cancer; BRAF wild type metastatic colorectal cancer; Left-sided metastatic colorectal cancer; Overall survival |
| Core Tip |
Anti-epidermal growth factor receptor (EGFR) therapy improves survival in RAS/BRAF wild-type metastatic colorectal cancer, whether used in frontline or subsequent settings. No direct evidence demonstrates frontline superiority, particularly in unresectable, left-sided tumors. Our study found no significant difference in overall survival (OS) between these approaches, suggesting timing does not affect OS if anti-EGFR therapy is administered. However, omitting frontline anti-EGFR risks some patients losing the chance to benefit later. These findings highlight the importance of early exposure and offer valuable guidance for optimizing treatment sequencing in this patient population. |
| Publish Date |
2025-01-21 09:22 |
| Citation |
<p>Pakvisal N, Goldberg RM, Sathitruangsak C, Silaphong W, Faengmon S, Teeyapun N, Teerapakpinyo C, Tanasanvimon S. Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer. <i>World J Clin Oncol</i> 2025; 16(3): 102076</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i3/102076.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i3.102076 |
